New vaccine study to investigate durability of COVID-19 immunity
UK Research and Innovation (UKRI) funding will support new research into the durability of COVID-19 immunity after vaccination and natural infection.
Third mRNA COVID vaccine dose could benefit immunocompromised dialysis patients
People who attend hospital for their dialysis treatment (haemodialysis) could benefit from an early third dose of an mRNA COVID-19 vaccine.
Blood clots in severe COVID cases may be related to abnormal antibody response
Inflammation and blood clotting seen in severe cases of COVID-19 may be caused by antibodies activating unnecessary platelet activity in the lungs.
New study sheds light on link between joint injury and osteoarthritis
Researchers investigated the factors underlying the association between acute knee injury and osteoarthritis, the most prevalent form of arthritis.
Long COVID research receives funding boost to advance treatment and diagnostics
Imperial academics have received funding from the National Institute of Health Research (NIHR) to support new research into long COVID.
New study set to investigate traumatic brain injury in armed forces personnel
The five-year project will investigate the effects of traumatic brain injury (TBI) in battlefield casualties from the UK Armed Forces.
First major study of new HIV therapy opens to recruitment
The RIO clinical trial will test whether a new type of therapy can keep HIV under control without daily antiretroviral treatment (ART) tablets.
Outstanding Infectious Disease staff celebrated at 2021 President’s Awards
Infectious Disease staff were recognised for their exceptional contributions to the College in this year’s President’s Awards for Excellence.
Video
Urgent action needed to reduce harm of ultra-processed foods to British children
British children are consuming ‘exceptionally high’ proportions of ultra-processed foods, increasing their risk of obesity and damaging their health.
Key enzyme aggravates colorectal cancer in obese patients
New research suggests the enzyme CES1 helps tumour cells to survive and drives aggressive colorectal cancer in obese patients.
